Phosphorylated Akt2 Capture Agents via Iterative Click Chemistry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and targeting phosphorylated Akt2, particularly in cancer diagnosis and therapy, face challenges due to the lack of effective small molecule inhibitors that can target the unstructured C-terminal epitope of Akt2.
Innovation Solution
Development of chemically synthesized capture agents, specifically protein-catalyzed capture agents (PCC Agents), that are designed to bind phosphorylated Akt2 using iterative in situ click chemistry, allowing for specific detection and potential therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule inhibitors are used to target Akt2, then the unstructured C-terminal epitope cannot be effectively targeted, but this limits the ability to detect and inhibit phosphorylated Akt2 in cancer
Solution Approach 1:
The patent uses a peptide ligand as an intermediary that specifically binds to the unstructured C-terminal epitope of Akt2. This peptide intermediary bridges the gap between the detection system and the previously inaccessible epitope, enabling reliable detection and targeting of phosphorylated Akt2 without requiring direct small molecule binding to the unstructured region
Solution Approach 2:
The invention changes the molecular parameters by using a peptide-based ligand instead of traditional small molecule inhibitors. This parameter change allows the ligand to adopt flexible conformations that can interact with the unstructured C-terminal epitope, thereby improving both targeting capability and epitope accessibility simultaneously
2Measurement precision
If chemically synthesized capture agents are developed to bind phosphorylated Akt2, then specificity and stability are improved, but the complexity of synthesis and characterization increases
Solution Approach 1:
The capture agent is segmented into distinct functional modules: a peptide ligand portion that provides specificity for phosphorylated Akt2, and a detectable label portion that enables detection. This segmentation allows independent optimization of binding specificity and detection capabilities, improving measurement precision while managing synthesis complexity through modular assembly
Solution Approach 2:
The patent creates simplified model systems and uses iterative in situ click chemistry to synthesize capture agents with controlled complexity. By using standardized peptide sequences and modular labeling approaches, the invention replicates successful binding motifs and detects Akt2 with high specificity without requiring excessively complex synthesis procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PCC Agents demonstrate high specificity and stability, effectively binding to phosphorylated Akt2 and indicating the presence of cancer, while also providing a potential means to inhibit Akt2 signaling.
Implementation Method 1
a stable, synthetic capture agent that specifically binds to phosphorylated Akt
Data Source
AI summary
The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.